Novaspira Biotherapeutics Reports Phase 1 Data for a Novel GPC3x4-1BB Bispecific in Late-Breaking Oral at SITC 2026

First-in-human Phase 1 results for BOS-342 (NS-342), a novel GPC3×4-1BB bispecific, demonstrate a manageable safety profile and durable antitumor activity.